{"id":789942,"date":"2023-10-12T10:32:56","date_gmt":"2023-10-12T14:32:56","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"modified":"2023-10-12T10:32:56","modified_gmt":"2023-10-12T14:32:56","slug":"adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","title":{"rendered":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"center\">\n        <em>&#8211; Data reinforces mechanism of action and selection of 10 mg\/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort \u2013<\/em>\n      <\/p>\n<p>SAN DIEGO and SUZHOU, China, Oct.  12, 2023  (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38<sup>th<\/sup> Annual Meeting taking place November 1-5, 2023 in San Diego.<\/p>\n<p>Details for the poster include:<\/p>\n<p>Title: <em>Optimal Dose Selection of ADG126 (a Masked anti-CTLA-4 SAFEbody\u00ae) with Significantly Widened Therapeutic Index compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling<\/em><\/p>\n<ul type=\"disc\">\n<li>Date: Friday, November 3<\/li>\n<li>Poster Hall Hours: 9:00 a.m. \u2013 7:00 p.m. (Reception: 5:10 p.m. \u2013 6:40 p.m.)<\/li>\n<li>Onsite Location: Exhibit Halls A and B1 \u2013 San Diego Convention Center<\/li>\n<li>Abstract Number: 847<\/li>\n<\/ul>\n<p>\n        <strong>About Adagene<\/strong>\n      <\/p>\n<p>Adagene Inc.\u00a0(Nasdaq: ADAG) is a platform-driven, clinical-stage biotechnology company committed to transforming the discovery and development of novel antibody-based cancer immunotherapies.\u00a0Adagene\u00a0combines computational biology and artificial intelligence to design novel antibodies that address unmet patient needs. Powered by its proprietary\u00a0Dynamic Precision Library\u00a0(DPL) platform, composed of NEObody\u2122, SAFEbody<sup>\u00ae<\/sup>, and POWERbody\u2122 technologies, Adagene\u2019s highly differentiated pipeline features novel immunotherapy programs.\u00a0Adagene\u00a0has forged strategic collaborations with reputable global partners that leverage its technology in multiple approaches at the vanguard of science.<\/p>\n<p>For more information, please visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=T1BEq2VBIZpxpZQWj0llbfifHHFEK27Y_CD-BClHEMYym3PkM15ehPvfAHL4LzEGkzo-irvqGinLI6qBzOMXqbgHFCtpsdgjr8XZM_IxD0Zb7x3gMIQjVfM2LpgP_jj7kMUu-tHsbewIzteq-65EmdyLY-E0KxYnkaLInkLT6Odi2uPBfj2OjxDFD1ai-WQwRvgJ8UrD6ebJQzlx_p-DtYRGiFLmZzIj14T-oqY6SAbypkZ9z6jRvOSIv_BGqfpn2i6U0nPa4CFLnxx4vWygcRdexcfRjXHNqp3yxYa8gFKQnhtMhXV6__cgDbXC5kU0NdySUN_dbWlp7Ym_Qfi0XgSimRZhK2xHTUSFVYHLLh4D4eD0UgYdVeDLJ5NmEu7xG2DgI8N3sFP31ZhOyv7-zAA0o07m0ey7TgkLolXxNhtB7-BHr9m3Pc5hFQl3a1Y70ewiS-OyqqkITLpmg-v20Y-udr5iRY7rTtBpKdCjrvrJS5IfEJtCnUWE4gkyrxxM\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/investor.adagene.com<\/a>. Follow\u00a0Adagene\u00a0on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=HNQpY2jkOKNrzFQyG9oVNh-nJpeggbtj88js5kUam58XvHHV46YzGHh-Tpd0jxo3VGGYtpkmGMH6W6uko0GFTkMD8hXTSnodqvszXsgq67YY35li0DXz-tTWPXSNjKhD7c1vquqaYQdoz9KELOvshAG41uRSUSpdaC15F39Awqdu2JEQjx1wUarW-cmtU7jo8e4ONTrYmcJys0vEEkek90fFW2cuB9CZVvJiVhOF7zLQ4tG7cNmCnOu8sxODP3NmkZHPovB-EDhS9a5cdY8PZPr3ipcYaf3R_7q-z3B_7csliI6fE7MayGyX4Efz2hd9N8e6ARcL3wk3eBpE45XWAfn9Vrx_nKquMrmSJeSgOGfHIzMuFQRerRsVxur5A7V_aZIC_SIgxcCBMeK8zokoYuEKqGZtQB-jfkFb0YGLh8wSKVRKXHjM8ZShfr8EFexntJKEUhtgbT2nPmTfTIfM6AnedSFZajam1hGufLNnujzwNQsmHxE9L3N82RxuYQguQfBkwydnJNtfVuPsJtNK2xX5g7j3fL499EB4TVdErjGwXBKjZEpiiAtkyx_D8XqYljW_zwiNY4B08rzpnOiTkw==\" rel=\"nofollow noopener\" target=\"_blank\">WeChat<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rs4A7u1KiUMI-Ts1q6NqjET7s713PmQBb0iliVmEvBTQNRk9H_-pLCXc9BPzCwUtkncxvRgW0NXvXkOopTUQxpS7NJu99JKf49WHAGJykzZGEX3CL3mO_1HpwNjAdZkkemvpKeU3K-Kwqs2F2FOGAsp6slF9kE2tLsX9d5uPvxIqtKJU5DoiyGH61_FPQgsOm6H53ETthzyiJfTiAPRrsZJSJVXnRvULh2jaO-jYu9AX-UAeKjNZlfFPSKH6Isye\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Yrdc0SRgJ5dC6oWoN-n6ywMucjOkxCkpIPpHNE6IeUDiSdAW5mDbBXZSG-Bl-Wm1-aOR46GoHvPIjR8jhxM1QreZsCqv_wZv2_BcDrZ0PKB0h6zergqQz-rs10GBNZ1FKSMcM0Qx3SkACM6LEyLf1T2UcxcennE61lH7BA_4pTZlIAXO-tZn9Yy5E3m6jfi_t1XdfG3isHdXkQ7X_cMn1oYk2Ik9uE2YihDFebg7IX8=\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>.\u00a0\u00a0<\/p>\n<p>SAFEbody<sup>\u00ae<\/sup>\u00a0is a registered trademark in\u00a0the United States,\u00a0China,\u00a0Australia,\u00a0Japan,\u00a0Singapore, and the\u00a0European Union.<\/p>\n<p>\n        <strong>Safe Harbor Statement<\/strong>\n      <\/p>\n<p>This press release contains forward-looking statements, including statements regarding certain clinical results of ADG126, the potential implications of clinical data for patients, and Adagene\u2019s advancement of, and anticipated preclinical activities, clinical development, regulatory milestones, and commercialization of its product candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including but not limited to Adagene\u2019s ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may not support further development or regulatory approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of Adagene\u2019s drug candidates; Adagene\u2019s ability to achieve commercial success for its drug candidates, if approved; Adagene\u2019s ability to obtain and maintain protection of intellectual property for its technology and drugs; Adagene\u2019s reliance on third parties to conduct drug development, manufacturing and other services; Adagene\u2019s limited operating history and Adagene\u2019s ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates; Adagene\u2019s ability to enter into additional collaboration agreements beyond its existing strategic partnerships or collaborations, and the impact of the COVID-19 pandemic on Adagene\u2019s clinical development, commercial and other operations, as well as those risks more fully discussed in the \u201cRisk Factors\u201d section in Adagene\u2019s filings with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Adagene, and Adagene undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required by law.<\/p>\n<p>\n        <strong>Investor &amp; Media Contact:<\/strong><br \/>\n        <br \/>Ami Knoefler<br \/>Adagene<br \/>650-739-9952<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=UXf1_mKynvTq-I--7-IuwpiDzBxMr8WJFe6FxCaZvHYHtJcITW_UDlbn8U28m8jRfiXQ9b3oiv8d8CpaTHqdlw==\" rel=\"nofollow noopener\" target=\"_blank\">ir@adagene.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/MWM3MTZhN2YtZjQwYi00MGVhLWIxOWUtMWViOTQ3YmQ1ZmFmLTEyMTYyMzQ=\/tiny\/Adagene-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>&#8211; Data reinforces mechanism of action and selection of 10 mg\/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort \u2013 SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego. Details for the poster include: Title: Optimal Dose Selection of ADG126 (a Masked anti-CTLA-4 SAFEbody\u00ae) with Significantly Widened Therapeutic Index compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling Date: Friday, November 3 Poster Hall Hours: 9:00 a.m. \u2013 7:00 p.m. (Reception: 5:10 p.m. &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-789942","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"&#8211; Data reinforces mechanism of action and selection of 10 mg\/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort \u2013 SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego. Details for the poster include: Title: Optimal Dose Selection of ADG126 (a Masked anti-CTLA-4 SAFEbody\u00ae) with Significantly Widened Therapeutic Index compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling Date: Friday, November 3 Poster Hall Hours: 9:00 a.m. \u2013 7:00 p.m. (Reception: 5:10 p.m. &hellip; Continue reading &quot;Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-12T14:32:56+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\",\"datePublished\":\"2023-10-12T14:32:56+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"},\"wordCount\":568,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\",\"name\":\"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\",\"datePublished\":\"2023-10-12T14:32:56+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","og_description":"&#8211; Data reinforces mechanism of action and selection of 10 mg\/kg every three weeks repeat dosing regimen with pembrolizumab in ongoing MSS CRC dose expansion cohort \u2013 SAN DIEGO and SUZHOU, China, Oct. 12, 2023 (GLOBE NEWSWIRE) &#8212; Adagene Inc. (\u201cAdagene\u201d) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based therapies, today announced its poster presentation at the SITC 38th Annual Meeting taking place November 1-5, 2023 in San Diego. Details for the poster include: Title: Optimal Dose Selection of ADG126 (a Masked anti-CTLA-4 SAFEbody\u00ae) with Significantly Widened Therapeutic Index compared to Ipilimumab in Combination with anti-PD-1 Antibodies Informed by QSP Modeling Date: Friday, November 3 Poster Hall Hours: 9:00 a.m. \u2013 7:00 p.m. (Reception: 5:10 p.m. &hellip; Continue reading \"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","og_site_name":"Market Newsdesk","article_published_time":"2023-10-12T14:32:56+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting","datePublished":"2023-10-12T14:32:56+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"},"wordCount":568,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/","name":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=","datePublished":"2023-10-12T14:32:56+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODk0ODEwMCM1ODY5NTgyIzIyMDQ2ODE="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/adagene-announces-poster-presentation-on-optimal-dose-selection-for-masked-anti-ctla-4-safebody-adg126-at-upcoming-society-for-immunotherapy-of-cancer-sitc-38th-annual-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Adagene Announces Poster Presentation on Optimal Dose Selection for Masked Anti-CTLA-4 SAFEbody\u00ae ADG126 at Upcoming Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/789942","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=789942"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/789942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=789942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=789942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=789942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}